R. Bansal

High-throughput measurement of the Tp53 response to anticancer drugs and random compounds using a stably integrated Tp53-responsive luciferase reporter

S. Kern, T. Sohn, R. Bansal, 2002 .

G1 cell cycle arrest and apoptosis induction by nuclear Smad4/Dpc4: phenotypes reversed by a tumorigenic mutation.

S. Kern, R. Bansal, J. Dai, 1999, Proceedings of the National Academy of Sciences of the United States of America.

Transforming growth factor‐β responsiveness in DPC4/SMAD4‐null cancer cells

S. Kern, M. Schutte, R. Bansal, 1999 .

Transforming growth factor-beta responsiveness in DPC4/SMAD4-null cancer cells.

S. Kern, M. Schutte, R. Bansal, 1999, Molecular carcinogenesis.

High-throughput measurement of the Tp53 response to anticancer drugs and random compounds using a stably integrated Tp53-responsive luciferase reporter.

S. Kern, T. Sohn, R. Bansal, 2003, Carcinogenesis.

Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%.

Kathleen M Murphy, Scott E Kern, Constance Griffin, 2002, Cancer research.

ACVR1B (ALK4, activin receptor type 1B) gene mutations in pancreatic carcinoma

R. Hruban, S. Kern, C. Yeo, 2001, Proceedings of the National Academy of Sciences of the United States of America.

Evidence of selection for clones having genetic inactivation of the activin A type II receptor (ACVR2) gene in gastrointestinal cancers.

B. Vogelstein, R. Hruban, C. Iacobuzio-Donahue, 2003, Cancer research.

Managing therapy-associated neurotoxicity in children with ALL.

R. Bansal, D. Bhojwani, A. Wayne, 2021, Hematology. American Society of Hematology. Education Program.

IT TAKES A VILLAGE: MAXIMIZING SUPPORTIVE CARE AND MINIMIZING TOXICITY DURING CHILDHOOD LEUKEMIA THERAPY

R. Bansal, D. Bhojwani, A. Wayne, 2021 .